Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea.
BMC Ophthalmol. 2022 Nov 8;22(1):426. doi: 10.1186/s12886-022-02668-5.
To compare the surgical outcomes and postoperative complications with and without Ologen collagen matrix augmentation during XEN gel stent implantation.
We retrospectively analyzed patients who underwent XEN gel stent implantation with an ab externo technique. The amount of intraocular pressure (IOP) reduction, percentage of postoperative complications and additional management, and surgical success defined as IOP reduction greater than 20% compared with the preoperative IOP measurement were compared between Ologen-augmented and non-augmented groups. Groups of patients who underwent XEN gel stent implantation alone and combined with phacoemulsification were analyzed separately.
A total 103 eyes of 103 participants were included. Of those, 72 eyes underwent standalone XEN gel stent implantation: 42 eyes with Ologen augmentation (Oloxen group) and 30 eyes without Ologen augmentation (Xen group). Thirty-one eyes underwent XEN gel stent implantation with phacoemulsification: 19 eyes with Ologen augmentation (Phaco-Oloxen group) and 12 eyes without Ologen augmentation (PhacoXen group). The surgical success rate at six months postoperatively was not different between the Oloxen and Xen groups (56.4% vs 43.3%, P > 0.05) or between the Phaco-Oloxen group and PhacoXen group (57.9% vs 41.7%, P > 0.05). The prevalence of postoperative hypotony, 5-fluorouracil injections, use of anti-glaucoma medications, bleb needling, and additional glaucoma surgeries was not different between the Oloxen and Xen groups or between the Phaco-Oloxen and PhacoXen groups when assessed six months postoperatively.
All groups showed significant IOP reduction after XEN gel stent implantation, but there was no significant difference between the Ologen collagen matrix augmented and non-augmented groups in surgical outcomes.
比较 Ologen 胶原基质增强与不增强在 XEN 凝胶支架植入过程中对手术结果和术后并发症的影响。
我们回顾性分析了采用经外路技术行 XEN 凝胶支架植入的患者。比较 Ologen 增强组和非增强组之间眼压（IOP）降低量、术后并发症及附加处理比例以及手术成功率（与术前 IOP 测量相比，IOP 降低超过 20%）。单独行 XEN 凝胶支架植入和联合超声乳化术的患者分组进行分析。
共纳入 103 名患者的 103 只眼。其中，72 只眼行单纯 XEN 凝胶支架植入：42 只眼行 Ologen 增强（Oloxen 组），30 只眼未行 Ologen 增强（Xen 组）。31 只眼行 XEN 凝胶支架植入联合超声乳化术：19 只眼行 Ologen 增强（Phaco-Oloxen 组），12 只眼未行 Ologen 增强（PhacoXen 组）。术后 6 个月手术成功率在 Oloxen 组和 Xen 组之间无差异（56.4%比 43.3%，P>0.05），在 Phaco-Oloxen 组和 PhacoXen 组之间也无差异（57.9%比 41.7%，P>0.05）。术后低眼压、5-氟尿嘧啶注射、使用抗青光眼药物、滤过泡针刺和额外的青光眼手术在 Oloxen 组和 Xen 组之间或 Phaco-Oloxen 组和 PhacoXen 组之间 6 个月时评估时无差异。
所有组在 XEN 凝胶支架植入后均有显著的 IOP 降低，但 Ologen 胶原基质增强与非增强组在手术结果方面无显著差异。
